Evaluation of the immunogenicity of aldhhigh human head and neck squamous cell carcinoma cancer stem cells in vitro 
Background
Using mouse models we reported that dendritic cells (DC) pulsed with cancer stem cells (CSC) enriched by virtue of their expression of the CSC marker aldehyde dehydrogenase (ALDH) significantly reduced development of pulmonary metastases and prolonged survival. In this recent study, we established the concept that the antigenicity/immunogenicity of ALDH high human head and neck squamous cell carcinoma (HNSCC) cancer stem cells is distinct from that of ALDH low non-CSCs.
Methods
Patients with HNSCC enrolled in the University of Michigan Special Project of Research Excellence (SPORE) were recruited to collect tumor and peripheral blood samples. T or B cells were purified from the PBMCs using anti-CD3-coupled or anti-CD19-coupled microbeads respectively with a MACS separator. Primary tumor samples were digested and collected. ALDE-FLUOR + /ALDH high or ALDEFLUOR -/ALDH low cells were isolated from tumor cells. ALDH low lysate-pulsed DCs (ALDH low -DC) or ALDH high lysate-pulsed DCs (ALDH high -DC, e.g. CSC-DC) were used as vaccines. To detect T and B cells in PBMCs, PBMCs were stained with PerCP mouse anti-human CD3 and FITC mouse anti-human CD19. Before sensitization in vitro, T or B cells were activated respectively with immobilized antihuman CD3 and anti-human CD28 in complete medium (CM) containing hrIL-2 or lipopolysaccharide plus antihuman CD45. Statistical analyses were performed to compare various interactions of the DC vaccine-primed/ sensitized T, B cells with autologous ALDH high CSC vs. ALDH low HNSCC target cells.
Results
DCs generated from the PBMC and pulsed with the lysate of ALDH high cells isolated from cultured HNSCC cells (CSC-DC) could sensitize autologous T, B lymphocytes in vitro, which was evident by cytokine production, CTL activity, and antibody secretion of these primed T, B cells in response to ALDH high CSCs. In contrast, DCs pulsed with lysate of ALDH low cells from the same HNSCC patient (ALDH low -DC) resulted in limited sensitization/priming of autologous T, B lymphocytes to produce IFNg, lyse CSCs, and secrete IgM and IgG in response to ALDH high CSCs.
Conclusions
These results demonstrated significant differences in the antigenicity/immunogenicity between ALDH high CSCs vs. ALDH low cells isolated from the tumor specimen of patients with HNSCC, which indicates the existence of unique CSC antigens in the ALDH high population. In addition, this study demonstrates that it is feasible to generate DCs from the PBMCs and isolate ALDH high CSCs from tumor cells of the patients with HNSCC to prepare CSC-DC vaccines for clinical application.
